|
|
|
|
|
|
|
|
press release
Study Using Patient-Derived Cells Within Human Extracellular Matrix (ECM) to Replicate Heterogeneous Tumor Microenvironments Aims to Improve Breast and Ovarian Cancer Treatment by Decreasing Anti-cancer Drug Failure Rates on a Large-Scale
SCOTTSDALE, AZ--(Marketwired - March 30, 2016) - Lattice Biologics Ltd. (TSX VENTURE: LBL)(OTCBB: BLVKF)
("Lattice Biologics" or the "Company") is pleased to announce it has
entered into an Industry Sponsored Collaboration Agreement with Sunnybrook Research Institute ("SRI") in Toronto, Ontario titled, "Conditional Reprogramming of Epithelial Cells to Determine Mechanisms of Resistance and Drug Sensitivity" (the
"Study"). The purpose of the Study is to develop new research methods,
including the creation of new instruments to make cellular measurements,
and the validation of methods to determine mechanisms of resistance and
drug sensitivity. The successful identification of such new methods
would lead to commercialization of high content screening (HCS)
chemosensitivity testing for cancer patients.
"We are extremely pleased to be working with such a prestigious
partner as Sunnybrook Research Institute to develop a personalized
approach for cancer diagnostics," states Guy Cook, Chief Executive Officer of Lattice Biologics Ltd.
"Lattice Biologic's ECM technology is revolutionary in its
unparalleled ability to accurately recreate complex tumor
microenvironments because it allows us to grow biopsies from patients'
own cancer tumors in the laboratory, subject the tumors to multiple
anti-cancer agents, and observe the resulting behaviors all while
sustaining natural conditions.
"This will provide a never-before-seen understanding of how
individual patients' tumors respond to specific treatments, allowing
physicians to prescribe anti-cancer treatments with new accuracy. This
level of personalized medicine will change the entire cancer
treatment game......
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.